In Japanese patients, approximately 50 and 5% of adenocarcinomas have a mutation in the epidermal growth factor receptor (EGFR) [1] and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene, respectively. This evidence concerns the gene ALK and adenocarcinoma.